WHO ICTRP trial
EUCTR2011-005239-14-FI · Pertti Suominen
EUCTR2011-005239-14-FI · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2011-005239-14-FI |
|---|---|
| Primary sponsor | Pertti Suominen |
| Secondary sponsors | Pertti Suominen |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): yes |
| Countries | Finland |
| Conditions | MedDRA version: 14.1 Level: LLT Classification code 10010495 Term: Congenital heart disease NOS System Organ Class: 10010331 - Congenital, familial and genetic disorders |
| Interventions | Trade Name: Solu-Medrol 40 mg/ml Pharmaceutical Form: Concentrate and solvent for injection Pharmaceutical form of the placebo: Infusion Route of administration of the placebo: Intravenous use Trade Name: Solu-Cortef 50 mg/ml injektio… |
| Registration date | May 1, 2012 |
| Target size | 40 |
| Secondary IDs | 062011 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: